Breaking News2 years ago
MEDSIR Study Finds No Progression-Free Survival Benefit with Palbociclib Maintenance After First-Line Regimen in HR+/HER2- Advanced Breast Cancer Patients
[ad_1] Newswise — JERSEY CITY, N.J., June 5, 2023 /PRNewswire/ — MEDSIR announced today the results of the PALMIRA trial. This randomized phase 2 study evaluated the safety and efficacy...
